| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$67,592,157 ) (Continued on the next page) |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 002 | 16 | NIH | 5/2/2023 | -$6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31AI150163 | Evolutionary dynamics of antibody affinity maturation | 001 | 3 | NIH | 5/15/2023 | -$1,526 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 16 | NIH | 12/13/2022 | -$2,672,807 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31NS118958 | Defining the role of C. elegans Parkin/PDR-1 in glial engulfment of neuron fragments | 002 | 2 | NIH | 5/15/2023 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 007 | 16 | NIH | 6/21/2023 | $6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 000 | 16 | NIH | 11/30/2022 | -$241,853 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$2,204,970 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 004 | 16 | NIH | 5/15/2023 | -$10,347 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3 | 027 | 16 | NIH | 7/20/2023 | -$49,588 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$3,817,177 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31NS118844 | Molecular mechanisms underlying neuronal integrity | 002 | 2 | NIH | 5/15/2023 | -$2,491 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 005 | 16 | NIH | 5/15/2023 | -$6,743 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3 | 026 | 16 | NIH | 7/20/2023 | -$500,081 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$125,000 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 003 | 3 | NIH | 11/28/2022 | -$28,853 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 002 | 3 | NIH | 11/28/2022 | -$22,711 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 16 | NIH | 1/3/2023 | -$125,000 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 001 | 3 | NIH | 11/28/2022 | -$89,755 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 006 | 16 | NIH | 2/7/2023 | -$1,564,038 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R03CA267113 | Type II diabetes, related biomarkers and medications, and ovarian cancer risk | 001 | 1 | NIH | 5/15/2023 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R21NS124191 | Discovery of sensorimotor connectivity mechanisms in a continuous topographic map | 000 | 1 | NIH | 11/15/2022 | -$4,431 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R21AI169085 | Integrating T cell receptor features with gene expression profiles to define T cell specificity and differentiation | 000 | 1 | NIH | 10/14/2022 | -$1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | K99NS121595 | Mechanisms of Target-Specific Axon Regeneration | 003 | 1 | NIH | 12/22/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31CA260920 | Elucidating the role of somatic 3?UTR mutations in prostate cancer pathogenesis | 001 | 2 | NIH | 5/15/2023 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 000 | 2 | NIH | 11/16/2022 | -$82,644 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | K99NS121595 | Mechanisms of Target-Specific Axon Regeneration | 000 | 1 | NIH | 11/30/2022 | -$2,958 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31CA260932 | Necrosis-mediated circulating tumor cell dissemination | 003 | 1 | NIH | 5/15/2023 | -$448 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 000 | 2 | NIH | 11/28/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI054423 | Genetic requirements of Helicobacter pylori infection | 002 | 17 | NIH | 6/15/2023 | -$1,829 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31CA260932 | Necrosis-mediated circulating tumor cell dissemination | 001 | 1 | NIH | 3/29/2023 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 008 | 16 | NIH | 6/21/2023 | $10,347 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F32CA254805 | Reactivation of an early embryonic program in FSHD and cancer | 002 | 2 | NIH | 5/15/2023 | -$2,026 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 002 | 16 | NIH | 12/19/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 002 | 16 | NIH | 12/19/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 001 | 16 | NIH | 12/13/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R35GM133441 | Investigating chromatin mechanisms using viral systems | 002 | 3 | NIH | 11/8/2022 | -$31,925 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 001 | 16 | NIH | 12/13/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 006 | 16 | NIH | 2/7/2023 | -$3,872,089 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01HL147324 | Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | 002 | 3 | NIH | 5/16/2023 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 002 | 16 | NIH | 5/2/2023 | -$10,347 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 001 | 15 | NIH | 11/21/2022 | $7,835,038 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | U54CA132381 | 2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch | 002 | 14 | NIH | 5/25/2023 | -$73,258 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01GM074108 | Genetic Conflict Shapes Centromeres and Heterochromatin | 000 | 16 | NIH | 11/7/2022 | -$15,654 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R21AI152559 | Immunogenetic determinants of HSV-2 infection and disease | 000 | 2 | NIH | 5/30/2023 | $0 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI147877 | Discovery and Characterization of Capsid-Targeting Lentiviral Restriction Factors | 004 | 3 | NIH | 5/25/2023 | $0 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA239287 | Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level | 001 | 3 | NIH | 5/15/2023 | $0 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 005 | 15 | NIH | 2/7/2023 | -$502,458 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01GM064386 | Regulation of Chromosome Segregation | 000 | 20 | NIH | 11/7/2022 | -$28 |
| | 2023 | 2021 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA119171 | Nutrition and Physical Activity Assessment Study | 000 | 14 | NIH | 5/15/2023 | $0 |
|
